Abstract
Pseudomonas aeruginosa is the most abundant bacterial species causing nosocomial infections in Russia. In this paper, we report the data on antimicrobial susceptibility of 743 isolates of P. aeruginosa collected in 63 hospitals of 22 cities of Russia in 2013-2014 as part of the national multicenter surveillance study on antimicrobial resistance of nosocomial pathogens, «MARATHON». P. aeruginosa isolates comprised 19.6% of all bacterial nosocomial isolates. Among them, the non-susceptibility rates to main antipseudomonal β-lactams were: 51.9% to cefepime, 55.9% to ceftazidime, 57.9% to piperacillin-tazobactam, 65.7% to imipenem, and 59.7% to meropenem. Production metallo-β-lactamases was detected in 21.3% of the isolates: VIM-type – 20.7, IMP-type – 0.5%. Most of the isolates were insusceptible to fluoroquinolones: ciprofloxacin (61.1%) and levofloxacin (62.8%), and to aminoglycosides: gentamicin (57.7%), amikacin (50.5%), and tobramycin (46.4%). Polymyxins had the highest in vitro activity with non-susceptibility rates being as low as 2.6% to colistin and strains not sensitivity to polymyxin B were not detected. Twenty nine percent of the isolates had the MIC of fosfomycin exceeding the epidemiological cut-off value of 128 mg/l. Notably, 51.4% of the isolates were categorised as extensively drug-resistant (XDR) and pan-resistance (PDR) strain was detected in 1 case.
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Rozanova S.M., Perevalova E.YU., Yaranceva N.Z. (Ekaterinburg)
Novikova R.I., Moldovanu M.G. (Izhevsk)
Valiullina I.R., Nasybullova Z.Z. (Kazan)
Arhipenko M.V., Adonina E.E., Petrova L.V., Nizhegorodceva I.A. (Krasnodar)
Lazareva A.V., Kryzhanovskaya O.A., Popov D.A., Zemlyanoj A.B., Zubrickij V.F., Aleksandrova I.A. (Moscow)
Gordeeva S.A., CHernyavskaya YU.L. (Murmansk)
Kirillova G.SH. (Noyabrsk)
Popova L.D., Elohina E.V. (Omsk)
Markelova N.N., Smolkova YU.E. (Penza)
Anikina I.N. (Petrozavodsk)
Shigorceva N.G., Zykova T.A., Kucevalova O.YU., Panova N.I. (Rostov-on-Don)
Borisov A.M., Bozhkova S.A., Suborova T.N., Poluhina O.V. (Saint-Petersburg)
Krechikova O.I. (Smolensk)
Shetinin E.V. Alieva E.V. (Stavropol)
Martyanova N.M. (Tolyatti)
Vunukajnen T.M., Gudkova L.V., Volkovskaya I.V. (Tomsk)
Hohlyavin R.L., Habibrahmanova D.F. (Tyumen)
Burasova E.G., Hrebtovskaya V.A. (Ulan-Ude)
Molchanova I.V. (Chelyabinsk)
SHamaeva S.H., Portnyagina U.S., Bryzgalova V.I., Yadreeva O.N. (Yakutsk)
-
1.
Решедько ГК, Рябкова ЕЛ, Фаращук АН и соавт. Неферментирующие грамотрицательные возбудители нозокомиальных инфекций в ОРИТ России: проблемы антибиотикорезистентности. Клин микробиол антимикроб химиотер 2006;8:243-59.
-
2.
Решедько ГК, Рябкова ЕЛ, Кречикова ОИ и соавт. Резистентность к антибиотикам грамотрицательных возбудителей нозокомиальных инфекций в ОРИТ многопрофильных стационаров России. Клин микробиол антимикроб химиотер 2008;10:96-112.
-
3.
Skleenova E, Sukhorukova M, Timokhova A, Martinovich A, Savochkina J, Edelstein M, Kozlov R. Sharp increase in carbapenem-non-susceptibility and carbapenemase production rates in nosocomial Gram-negative bacteria in Russia over the last decade. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2012, Denver, CO, USA. Abstract C2- 1092.
-
4.
Эйдельштейн МВ, Склеенова ЕЮ, Шевченко ОВ и соавт. Распространенность и молекулярная эпидемиология грамотрицательных бактерий, продуцирующих металло-бета-лактамазы, в России, Беларуси и Казахстане. Клин микробиол антимикроб химиотер 2012;14:132-52.
-
5.
Сухорукова МВ, Эйдельштейн МВ, Склеенова ЕЮ и соавт. Антибиотикорезистентность нозокомиальных штаммов Pseudomonas aeruginosa в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011–2012 гг. Клин микробиол антимикроб химиотер 2014;16:273-9.
-
6.
Breidenstein EB, de la Fuente-Nunez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 2011;19:419-26.
-
7.
Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014;15:1351-70.
-
8.
Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18(2):306-25.
-
9.
Edelstein MV, Skleenova EN, Shevchenko OV, D'souza JW, Tapalski DV, Azizov IS, Sukhorukova MV, Pavlukov RA, Kozlov RS, Toleman MA, Walsh TR. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013;13:867-76.
-
10.
ISO 20776-1:2006 «Clinical laboratory testing and in vitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices» - Part 1 : Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases.
-
11.
Национальный Стандарт ГОСТ Р ИСО 20776-1-2010 Клинические лабораторные исследования и диагностические тест-системы in vitro. Исследование чувствительности инфекционных агентов и оценка функциональных характеристик изделий для исследования чувствительности к антимикробным средствам. Часть 1. Референтный метод лабораторного исследования активности антимикробных агентов против быстрорастущих аэробных бактерий, вызывающих инфекционные болезни.
-
12.
Клинические рекомендации «Определение чувствительности микроорганизмов к Антимикробным препаратам». Версия 2015-02. Доступно по URL: http://www.antibiotic.ru/minzdrav/files/docs/clrec-dsma2015.pdf
-
13.
European Committee on Antimicrobial Susceptibility testing (EUCAST). EUCAST breakpoints for ceftazidime-avibactam. Available at URL: http://www.eucast.org/clinical_breakpoints/
-
14.
van der Zwaluw K, de Haan A, Pluister GN, Bootsma HJ, de Neeling AJ, Schouls LM. The Carbapenem inactivation method (CIM), a simple and lowcost alternative for the Carba NP test to assess phenotypic carbapenemase activity in Gram-negative rods. PLOS One 2015;10: e0123690.
-
15.
Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.